WO2018194879A1 - Procédé de fabrication d'un timbre transdermique de fentanyl avec distribution uniforme de cristaux de médicament - Google Patents

Procédé de fabrication d'un timbre transdermique de fentanyl avec distribution uniforme de cristaux de médicament Download PDF

Info

Publication number
WO2018194879A1
WO2018194879A1 PCT/US2018/026802 US2018026802W WO2018194879A1 WO 2018194879 A1 WO2018194879 A1 WO 2018194879A1 US 2018026802 W US2018026802 W US 2018026802W WO 2018194879 A1 WO2018194879 A1 WO 2018194879A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
adhesive
medical device
solvent
suspension
Prior art date
Application number
PCT/US2018/026802
Other languages
English (en)
Inventor
Spiros Fotinos
Jerome LANGLUME
Jean Paul CARAVITA
Original Assignee
Inep Europe Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/491,419 external-priority patent/US11052054B2/en
Priority claimed from US15/492,146 external-priority patent/US10377114B2/en
Priority claimed from US15/838,837 external-priority patent/US20180303764A1/en
Priority claimed from US15/838,977 external-priority patent/US10391065B2/en
Application filed by Inep Europe Sarl filed Critical Inep Europe Sarl
Priority to EP18788597.5A priority Critical patent/EP3612170A4/fr
Publication of WO2018194879A1 publication Critical patent/WO2018194879A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Definitions

  • the present invention relates to a transdermal fentanyl patch with even drug crystal distribution.
  • a conventional transdermal delivery patch has been described in U.S. Patent No. 7,247,315.
  • the patch includes a solid drug reservoir medical device for transdermal administration of a drug.
  • the medical device has four layers, from top to bottom, a backing, a solid drug reservoir, a rate-controlling membrane, and an adhesive layer.
  • the adhesive layer is covered with a release liner.
  • the physical structure of this device is similar to a liquid reservoir fentanyl patch as described in U.S. Patent No. 4,588,580.
  • the main difference in structure between the solid reservoir patch and the fentanyl patch described in U.S. Patent No. 4,588,580 is that the reservoir layer of the original fentanyl patch was primarily liquid in composition, while the reservoir of U.S. Patent No.
  • 7,247,315 is a solid adhesive material.
  • the liquid reservoir of the fentanyl patch described in U.S. Patent No. 4,588,580 is contained physically within the patch by a peripheral seal around the edge of the patch, joining the backing to the rate-controlling membrane at the edges, sealing the liquid reservoir between the backing and the rate- controlling membrane. No peripheral seal is needed for the solid reservoir patch described in U.S. Patent No. 7,247,315.
  • the process for manufacturing the device of U.S. Patent No. 7,247,315 includes a step for manufacturing the solid drug reservoir by which the active ingredient, fentanyl base, was present in solution with the adhesive in the coating composition that was used to produce the solid adhesive reservoir.
  • the drug/adhesive solution was applied to a substrate and passed through an oven to evaporate the solvent. After this coated drug adhesive composition exited the coating oven, with low levels of residual solvent after evaporation, the drug recrystallized within the solid drug reservoir.
  • the resulting composition contained recrystallized drug in a form that was not well-defined when viewed microscopically as shown in Fig. 9.
  • the drug particles were small and formed agglomerates.
  • fentanyl patch having a composition including a drug- containing layer of the patch manufactured in a manner so that the appearance of drug particles in the product is controlled and the drug particles can be characterized according the Development Principles for passive transdermal systems.
  • the present invention provides a method of manufacture for a composition suitable for use in a medical device that does not include a process step by which complete dissolution of the drug occurs.
  • the method of manufacture for a composition suitable for use in a medical device of the present invention includes the step of producing a solid drug reservoir layer for use in the medical device.
  • the drug is first dispersed in a solvent in a ratio of about 2: 1 or 3 : 1
  • the drug can be dispersed in heptane, at a ratio of about 2: 1 or 3 : 1 heptane:drug w/w. This mixture is stirred to blend the drug uniformly in the dispersion with heptane.
  • a suitable drug is fentanyl.
  • Fentanyl has a finite solubility in heptane.
  • This suspension is added quantitatively to an adhesive solution.
  • a dimethicone such as Medical Fluid
  • An analysis of heptane from a sample of this mixture after the undissolved drug is separated by filtration provides a measure of the amount of the fentanyl that has dissolved in the heptane.
  • the drug is suspended in the adhesive mixture rather than dissolved.
  • the drug adhesive solution mixture is then coated on a backing layer, forming a drug reservoir layer after evaporation of the solvent. By this process, crystalline drug is present within the drug reservoir layer immediately after the coating process.
  • the medical device produced by the method of the present invention is for transdermal administration of a drug through an area of human skin during an
  • the drug may be micronized prior to suspension in the heptane.
  • the particle size of the drug in the product may be controlled through control of particle size of the raw material active pharmaceutical ingredient (API) input to the process in the suspension with heptane.
  • API active pharmaceutical ingredient
  • the drug particles in the finished product are not larger than the initial particle size of the drug as it is suspended in the heptane.
  • the drug does not re-crystallize in the drug adhesive after coating.
  • the crystalline drug particles in the drug adhesive remain in the same form and remain crystalline throughout the entire process.
  • FIG. 1 is a schematic illustration of a solid reservoir transdermal drug delivery device of the present invention.
  • Fig. 2 is a schematic illustration of a monolith transdermal drug delivery device of the present invention.
  • Fig. 3 is a comparison of the solid drug reservoir patch of the present invention and the prior art liquid reservoir patch as described in U.S. Patent No. 4,588,580.
  • Fig. 4 is a photomicrograph showing the drug particles in product manufactured by the prior art method described in U.S. Patent No. 7,247,315.
  • Fig. 5 is a graph showing the particle size distribution of one batch of micronized raw material API (fentanyl) used in the manufacture of a product by the present invention.
  • Fig. 6 is a photomicrograph showing the drug particles in the product
  • Figures 7 A and 7B are photomicrographs showing the drug particles in a product manufactured by the present invention, showing the same microscopic view in the same section of product at different times after manufacture.
  • Fig. 8 is a photomicrograph of a prior art commercially available Duragesic ® fentanyl transdermal medical device showing the distribution of drug particles within the product.
  • Fig. 9A is a photomicrograph of the product manufactured by the present invention and Fig. 9B is a photomicrograph of the liquid reservoir patch described in prior art U.S. Patent No. 4,588,580, adjusted to similar scale for direct comparison of particle size and distribution in the two patches.
  • the present invention relates to a drug containing composition that can be manufactured in a manner that provides control of the particle size of the drug in the finished product through control of the particle size of the active pharmaceutical ingredient (API) input to the process.
  • the process of the present invention results in a very even distribution of the drug particles in a solid drug adhesive layer as viewed and measured by microscopy. This improved process allows characterization of the appearance of drug particles, changes in particle form, size, shape, habit, or aggregation that may occur during the course of product processing and storage, as specified in Development Principles in AAPS PharmSciTech (DOI: 10.1208/sl2249-01 1-9740-9).
  • a preferred method for preparing the drug-containing compositions of the present invention comprises micronizing a raw material active pharmaceutical ingredient (API) to a specified particle size/distribution.
  • the raw material active pharmaceutical ingredient (API) can be fentanyl and analgesically effective derivatives thereof as the drug, it should be understood that other drugs are also suitable for use with the teachings of the present invention including: sufentanil oxymorphone, oxycodone, hydromorphone, morphine, buprenorphine and analgesically effective derivatives thereof.
  • the particle size is selected based on several criteria.
  • the particle size/distribution should be small so that the finished product contains particles with high specific surface area so that dissolution from drug particles does not limit the rate of drug release from the finished product.
  • the drug particles should be small enough so that all particles pass easily through all apertures present in the manufacturing process, such as the gap in the coating die.
  • the drug particles should be small enough so that any tendency for settling of drug particles in suspension is minimized.
  • the drug particles should not be so small that there is difficulty in transfer of the raw material to the suspension (no aerosolization).
  • the particle size distribution should be chosen so that no particles are greater in size than about 40 microns and the D(90) particle size distribution is greater than about 3 microns.
  • An adhesive is received in a solution with a solvent to form an adhesive solution.
  • the solvent can be heptane.
  • the adhesive and solvent can be received separately, and dissolution of the adhesive in the solvent will be an additional step in the process.
  • Example adhesives include amine resistant silicone adhesive.
  • Suitable amine resistant silicone adhesive matrix material compositions include any type of "high tack" polydimethylsiloxane with an average molecular weight of between 100,000 and 5,000,000, preferably 500,000 and 1,500,000.
  • the micronized fentanyl or sufentanil is added to a quantity of solvent, for example heptane.
  • the micronized fentanyl or sufentanil is first dispersed in a solvent in a ratio of about 2: 1 or 3 : 1.
  • the micronized fentanyl or sufentanil can be dispersed in heptane, at a ratio of about 2: 1 or 3 : 1 heptane: fentanyl or heptane sufentanil w/w.
  • This mixture is stirred to blend the fentanyl or sufentanil uniformly in the dispersion with heptane to create uniform suspension of the fentanyl or sufentanil in the solvent.
  • the dispersion of fentanyl or sufentanil in dispersion is quantitatively added to the adhesive solution to transfer substantially all of the fentanyl and sufentanil in dispersion to the adhesive solution.
  • plasticizer can be added to the suspension, at the proper ratio, so that when the solvent is removed by evaporation the plasticizer will be present in the dried adhesive at the correct concentration.
  • plasticizers include low molecular weight polydimethylsiloxane described in the National Formulary as
  • the solvent should be selected so that the fentanyl or sufentanil particles become suspended in the solvent; and, when the suspension of fentanyl in the solvent with plasticizer is added to the adhesive solution, the drug particles remain suspended without dissolving and the adhesive remains dissolved.
  • the medical device produced by the method of the present invention is for transdermal administration of a drug through an area of human skin during an
  • the medical device comprising:
  • a solid drug reservoir layer having a top side and a bottom side and an external edge, wherein the solid drug reservoir layer is a composition formed by the method of the present invention; a rate-controlling membrane having a top and a bottom side, wherein the top side of the rate-controlling membrane is contiguously disposed with respect to the bottom side of the solid drug reservoir layer; and
  • an adhesive layer having a top and a bottom side, wherein the top side of the adhesive layer is contiguously disposed with respect to the bottom side of the rate- controlling membrane.
  • the present invention provides a multilaminate medical device.
  • a schematic illustration of a multilaminate transdermal drug delivery device 100 embodiment of the present invention comprises a backing layer 110, a drug reservoir layer 120, a rate controlling membrane 130, an adhesive layer 140 and a strippable release liner 150.
  • the backing layer 110 can be any backing layer described above, such as a 1-5 mil thick multilaminate comprising PET and EVA. In some embodiments, the backing layer 110 can be impermeable to liquids from outside medical device.
  • the solid drug reservoir layer 120 comprises a matrix material such as an amine resistant silicone adhesive and a fentanyl flux rate lowering amount of one or more suitable plasticizer(s) such as polydimethylsiloxane (e.g., Medical Fluid 360 from Dow Corning).
  • the solid drug reservoir composition also has a dissolved and suspended drug within the solid drug reservoir layer 120.
  • the drug composition is fentanyl, a fentanyl derivative, or a pharmaceutically acceptable salt thereof.
  • the peripheral edge 122 of the solid drug reservoir layer 120 is unsealed, and can be exposed to air, in the medical device product of the invention shown in FIG. 1.
  • the rate controlling membrane 130 comprises low density polyethylene, polyethylene-(vinyl acetate) copolymers (with up to 40% vinyl acetate, preferably between 5 and 19% vinyl acetate, and most preferably 19%) vinyl acetate).
  • the thickness of the rate controlling membrane 130 can be adjusted with the 20 percent vinyl acetate in the composition to provide a selected fentanyl flux rate, as discussed above.
  • the rate controlling membrane 130 is between about 0.5 to 5.0 mils (that is, about 0.0127 to 0.1270 inches) thick.
  • the adhesive layer 140 is comprised of the same matrix material composition and a similar type of flux rate lowering plasticizer as the solid drug reservoir composition 120.
  • the adhesive layer 140 comprises a flux rate lowering effective amount of the plasticizer(s) present in the solid drug reservoir layer 120.
  • the adhesive layer 140 comprises the same plasticizer(s) present in the solid drug reservoir layer 120 in approximately the same weight percentage(s).
  • the strippable release liner 150 can be any release liner described above, such as a 3 mil thick fluorocarbon diacrylate or silicone (polysiloxane) coated polyester film.
  • the various layers are laminated or otherwise assembled into a transdermal drug delivery device, such as a bandage or patch, having a medically appropriate predetermined size and shape as known in the art. While FIG.
  • both layers preferably comprise matrix materials and plasticizer(s) that are similar in type and amount.
  • FIG. 2 is a schematic illustration of a monolith medical device 200 for trans dermal drug delivery.
  • a medical device 200 comprises a backing layer 210, a drug reservoir adhesive layer 220 and a strippable release liner 230.
  • the backing layer 210 can be any backing layer described above, such as a 1-5 mils thick multi laminate comprising PET and EVA. In some embodiments, the backing layer 210 can be impermeable to liquids from outside medical device.
  • the drug reservoir adhesive layer 220 comprises a matrix material such as an amine resistant silicone adhesive and a fentanyl flux rate lowering amount of one or more suitable plasticizer(s) such as a polydimethylsiloxane emulsion (e.g., Medical Fluid 360 from Dow Corning).
  • the drug reservoir adhesive layer 220 can comprise about 70-95% w/w of a polysiloxane-based adhesive matrix material, about 4-20% w/w polydimethylsiloxane-type plasticizer and about 2- 15%) w/w of the fentanyl drug composition.
  • the drug reservoir adhesive layer 220 in a monolith medical device 200 can serve as both a solid drug reservoir and as an adhesive layer to maintain the monolith medical device 200 in transdermal drug flux permitting contact with a subject's skin throughout an administration period.
  • the drug reservoir adhesive layer 220 composition has a dissolved and suspended drug within the drug reservoir adhesive layer 220.
  • the drug composition is fentanyl, a fentanyl derivative, or a pharmaceutically acceptable salt thereof.
  • the peripheral edge 222 of the drug reservoir adhesive layer 220 is unsealed, and can be exposed to air, in the medical device product of the invention shown in Fig. 2.
  • Fig. 3 is a comparison of the solid drug reservoir patch of the current invention and the prior art liquid reservoir patch described in U.S. Patent No. 4,588,580.
  • Fig. 4 is a photomicrograph of a patch showing the appearance of drug particles in a product manufactured by the prior art method described in U.S. Patent No. 7,247,315. Individual drug particles can not be distinguished in this photomicrograph. The drug particles are present as agglomerates that appear like "clouds" within the formulation.
  • Fig. 5 is a graph showing the particle size distribution by volume of one batch of micronized raw material API (fentanyl) used in the manufacture of product by the present invention.
  • D(90) is about 8.2 microns
  • D(50) is about 4.2 microns
  • the analysis detects no particles larger than 25 microns.
  • Fig. 6 is a photomicrograph of product manufactured according to the present invention, using the batch of micronized drug that is described by Fig. 5. This photomicrograph shows the individual drug particles are more evenly distributed in the product in comparison with product of the prior art shown in Fig. 4, and the individual drug particles can be distinguished within the product.
  • Figs. 7A-7B When the same view of the patch in Fig. 6 is examined at different times after production, as shown in Figs. 7A-7B, there is no visible change in the drug particles.
  • the drug particles can be distinguished in sufficient detail to determine the size and appearance of the drug particles does not change over time.
  • Fig. 8 is a photomicrograph showing the particle size and distribution of the drug in a prior art commercially available Duragesic® fentanyl transdermal medical device. This photomicrograph demonstrates there is high variability in the particle size and the physical distribution of the drug in this product.
  • Figs. 9A and 9B show two photomicrographs, adjusted to similar scale, comparing of the particle size and particle size distribution of the product of the present invention with the original liquid reservoir fentanyl patch. This comparison shows the product of the present invention contains small drug particles relative to the liquid reservoir patch, and the size of the particles in the product of the present invention is much more uniform than the size of the drug particles in the prior art liquid reservoir patch. In addition, the drug particles in product of the present invention are much more evenly distributed over the area of the patch than drug particles in the liquid reservoir patch.
  • the product manufactured by the present invention has the following attributes:
  • the drug particles in the product are small and evenly distributed in the product in comparison to other fentanyl patches.
  • the drug particles are present in the solid drug reservoir layer of the patch and not in the second adhesive layer, the skin adhesive, below the rate-controlling membrane
  • the crystalline form of the drug particles in the product is the same as the crystalline form of the raw material API input to the process.

Abstract

L'invention concerne des procédés de production d'un timbre d'administration transdermique comprenant la préparation d'une suspension uniforme de particules de médicament. Un plastifiant est ajouté à la suspension. Une solution d'un adhésif est ajoutée à la suspension pour former une suspension de médicament dans le mélange adhésif. La suspension de médicament est revêtue sur revêtement anti-adhérent et tous les solvants sont évaporés pour former une couche de réservoir de médicament solide. Un dispositif médical pour l'administration transdermique d'un médicament peut comprendre la couche de réservoir de médicament solide. Les médicaments appropriés comprennent le fentanyl et le sufentanil.
PCT/US2018/026802 2017-04-19 2018-04-10 Procédé de fabrication d'un timbre transdermique de fentanyl avec distribution uniforme de cristaux de médicament WO2018194879A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18788597.5A EP3612170A4 (fr) 2017-04-19 2018-04-10 Procédé de fabrication d'un timbre transdermique de fentanyl avec distribution uniforme de cristaux de médicament

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15/491,419 2017-04-19
US15/491,419 US11052054B2 (en) 2017-04-19 2017-04-19 Method for manufacturing a transdermal device
US15/492,146 2017-04-20
US15/492,146 US10377114B2 (en) 2017-04-20 2017-04-20 Method for making a transdermal fentanyl patch with even drug crystal distribution
US15/838,837 2017-12-12
US15/838,837 US20180303764A1 (en) 2017-04-19 2017-12-12 Method for manufacturing a transdermal device
US15/838,977 2017-12-12
US15/838,977 US10391065B2 (en) 2017-04-19 2017-12-12 Method for making a transdermal fentanyl patch with even drug crystal distribution

Publications (1)

Publication Number Publication Date
WO2018194879A1 true WO2018194879A1 (fr) 2018-10-25

Family

ID=63856066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/026802 WO2018194879A1 (fr) 2017-04-19 2018-04-10 Procédé de fabrication d'un timbre transdermique de fentanyl avec distribution uniforme de cristaux de médicament

Country Status (2)

Country Link
EP (1) EP3612170A4 (fr)
WO (1) WO2018194879A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010033858A1 (en) * 2000-02-29 2001-10-25 Jie Zhang Transdermal drug patch
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
US20090238861A1 (en) * 2002-10-30 2009-09-24 Mylan Pharmaceuticals, Inc. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
US20140276478A1 (en) * 2013-03-15 2014-09-18 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of tertiary amine drugs
WO2016149077A2 (fr) * 2015-03-13 2016-09-22 Amneal Pharmaceuticals Llc Système d'administration transdermique de fentanyl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2348397C2 (ru) * 2003-02-07 2009-03-10 Лтс Ломанн Терапи-Системе Аг Трансдермальная терапевтическая система, пригодная для использования тепла с целью ускорения проникновения биологически активных веществ, и ее применение
EP2111857A1 (fr) * 2008-04-25 2009-10-28 Acino AG Système thérapeutique transdermique destiné à l'application de fentanyle ou d'une matière analogue
EP2295046B1 (fr) * 2009-09-14 2012-12-19 Acino AG Système thérapeutique transdermique destiné à l'application de fentanyle ou d'une matière analogue

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365178B1 (en) * 1996-09-06 2002-04-02 Watson Pharmaceuticals, Inc. Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions
US20010033858A1 (en) * 2000-02-29 2001-10-25 Jie Zhang Transdermal drug patch
US20090238861A1 (en) * 2002-10-30 2009-09-24 Mylan Pharmaceuticals, Inc. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
US20140276478A1 (en) * 2013-03-15 2014-09-18 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of tertiary amine drugs
WO2016149077A2 (fr) * 2015-03-13 2016-09-22 Amneal Pharmaceuticals Llc Système d'administration transdermique de fentanyl

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3612170A4 *

Also Published As

Publication number Publication date
EP3612170A1 (fr) 2020-02-26
EP3612170A4 (fr) 2021-01-27

Similar Documents

Publication Publication Date Title
US8617591B2 (en) Transdermal delivery system for the administration of rotigotine
US7556823B2 (en) Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
EP2515887B1 (fr) Polyvinylpyrrolidone destinée à la stabilisation d'une dispersion solide de la forme non cristalline de la rotigotine
EP1524975B9 (fr) Systeme d'administration transdermique ameliore pour administrer la rotigotine
JPH05194202A (ja) 活性物質としてチュロブテロールを有する医療システム
US20040081683A1 (en) Transdermal delivery system
JP2011518795A (ja) フェンタニルまたはその類似化合物を投与するための経皮治療システム
CN110251490A (zh) 低自结晶倾向的透皮治疗系统
EP1524971B1 (fr) Systeme d'administration transdermique ameliore
US10391065B2 (en) Method for making a transdermal fentanyl patch with even drug crystal distribution
US10377114B2 (en) Method for making a transdermal fentanyl patch with even drug crystal distribution
WO2018194879A1 (fr) Procédé de fabrication d'un timbre transdermique de fentanyl avec distribution uniforme de cristaux de médicament
US20190365663A1 (en) Method for making a transdermal fentanyl patch with even drug crystal distribution
TW200831142A (en) Manufacturing apparatus of transdermal absorption preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18788597

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018788597

Country of ref document: EP

Effective date: 20191119